Teva digital inhaler
The inhaler is nothing new in the world of drug delivery, but Teva Respiratory (NYSE:TEVA) is taking the device a step further.
Last September, the U.S. affiliate of Teva Pharmaceutical Industries launched its AirDuo Digihaler and ArmonAir Digihaler digital inhalers in the U.S., bringing new forms of treatment for symptoms of asthma.
The AirDuo Digihaler is a prescription inhalation powder for controlling symptoms of asthma and preventing including wheezing in those 12 years old and up. The ArmonAir Digihaler is a prescription medicine designed for the long-term treatment of asthma in patients 12 years of age or older.
Both products include built-in Bluetooth technology, allowing for the connection to a companion mobile app to compile data on inhaler use, which is recorded as an event when the cap is opened or a patient inhales. The digihalers automatically detect, record and store data and can remind the patient how often devices have been used and determine if they need to improve their inhalation technique.
Neither of the Digihalers are used to relieve sudden breathing problems from asthma and they will not replace the need for a rescue inhaler.
